Alvotech (ALVO) Other Non-Current Liabilities (2020 - 2026)
Alvotech's (ALVO) quarterly Other Non-Current Liabilities came in at $21.8 million in Q1 2026, down 89.65% YoY from $210.2 million in Q1 2025, and down 59.69% on a QoQ basis from $54.0 million in Q4 2025.
Alvotech (ALVO) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Alvotech (ALVO) has 7 years of Other Non-Current Liabilities data on file, last reported at $21.8 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 89.65% year-over-year to $21.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.8 million (down 89.65% YoY) and the FY2025 annual result came in at $54.0 million, down 74.32% from the prior year.
- Other Non-Current Liabilities fell to $21.8 million in Q1 2026, from $54.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $520.6 million in Q1 2023 to a low of $21.8 million in Q1 2026.
- A 5-year average of $238.0 million and a median of $210.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 3285977.26% — and 2026, when it slumped 89.65%.
- Tracing ALVO's Other Non-Current Liabilities over 5 years: stood at $380.2 million in 2022, then jumped by 36.9% to $520.6 million in 2023, then plunged by 59.62% to $210.2 million in 2024, then plunged by 74.32% to $54.0 million in 2025, then plunged by 59.69% to $21.8 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $21.8 million (Q1 2026), $54.0 million (Q4 2025), and $210.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Alvotech | 1.30 Bn | 1.30 Bn | 5.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.76 Mn |
| Dec 31, 2025 | 53.99 Mn |
| Sep 30, 2025 | 210.22 Mn |
| Jun 30, 2025 | 63.00 Mn |
| Mar 31, 2025 | 210.22 Mn |
| Dec 31, 2024 | 210.22 Mn |
| Sep 30, 2024 | 182.36 Mn |
| Jun 30, 2024 | 201.67 Mn |
| Mar 31, 2024 | 330.98 Mn |
| Dec 31, 2023 | 520.55 Mn |
| Jun 30, 2023 | 229.05 Mn |
| Mar 31, 2023 | 520.58 Mn |
| Dec 31, 2022 | 380.23 Mn |
| Jun 30, 2022 | 197.47 Mn |
| Dec 31, 2021 | 11,571.00 |
| Dec 31, 2020 | 534.69 Mn |